The Defense Advanced Research Projects Agency (DARPA) in the US has awarded a contract to AnaptysBio to generate antibodies to detect toxic substances and bio-terrorist threats.
Under the two-year, $1.5m contract, the company will use its somatic hypermutation (SHM) technology platform to produce high-affinity thermally stable antibodies for military applications and safety-related equipments.
Go deeper with GlobalData
Antibodies, an important component of biosensors, can sense toxic substances and are used to detect potential bio-terrorist threats.
AnaptysBio chairman and CEO Tom Smart said SHM has the potential to generate improved antibodies, which in turn can be used in biosensors with full retention of functionality.
“The results also may have applications within the pharmaceutical industry for more flexible and less costly formulation and storage requirements for therapeutic antibodies,” Smart said.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
